CompletedPhase 4NCT00520494
Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency
Studying Agammaglobulinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CSL Behring
- Principal Investigator
- Michael Borte, MDKlinik für Kinder-und Jugendmedizin am Städtischen Klinikum St. Georg, Leipzig, Germany
- Intervention
- Vivaglobin(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 1-70 years · All sexes
- Timeline
- 2007 – 2008
Study locations (6)
- Contact CSL Behring for facility details, Edmonton, Alberta, Canada
- Contact CSL Behring for facility details, Montreal, Quebec, Canada
- Contact CSL Behring for facility details, Leipzig, Germany
- Contact CSL Behring for facility details, Brescia, Italy
- Contact CSL Behring for facility details, Roma, Italy
- Contact CSL Behring for facility details, Madrid, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00520494 on ClinicalTrials.govOther trials for Agammaglobulinemia
Additional recruiting or active studies for the same condition.